-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653.Oral1.3 653. Myeloma: Therapy, excluding Transplantation: Immunotherapy in Myeloma and Amyloid

Myeloma: Therapy, excluding Transplantation Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
antibodies, Biological, multiple myeloma, Diseases, Therapies, Mechanisms, CAR-Ts, Clinically relevant, Lymphoid Malignancies, immunotherapy, Plasma Cell Disorders, immune mechanism
Sunday, December 10, 2017: 4:30 PM-6:00 PM
Bldg C, Lvl 1, Hall C4 (Georgia World Congress Center)
Moderators:
Dan T. Vogl, MD, University of Pennsylvania and Yvonne A Efebera, MD, The Ohio State University
Disclosures:
Vogl: Karyopharm: Consultancy; Takeda: Consultancy, Research Funding; Amgen: Consultancy; Celgene: Consultancy; Janssen: Consultancy; Teva: Consultancy; Calithera: Research Funding; GSK: Research Funding; Constellation: Research Funding. Efebera: karypharm: Honoraria, Other: Adjudication Commitee; Janssen: Speakers Bureau; Takeda: Other: Adjudication Committee, Speakers Bureau; Celgene: Research Funding.
4:30 PM

Adam D. Cohen, MD1, Alfred L. Garfall, MD1, Edward A. Stadtmauer, MD, FACP1*, Simon F Lacey, PhD, BS2, Eric Lancaster3*, Dan T. Vogl, MD1, Brendan M Weiss, MD1, David E Ambrose, BS4*, Anne Marie Nelson4*, Fang Chen, PhD4*, Gabriela Plesa, MD4*, Irina Kulikovskaya4*, Vanessa Gonzalez4*, Minnal Gupta4*, Regina M Young, PhD2*, Karen Dengel, BSN, RN4*, Laura O'keefe4*, Samantha Le4*, Celeste Richardson, PhD5*, Randi E. Isaacs, MD5*, J. Joseph Melenhorst, PhD4, Bruce L Levine, PhD4, Carl H June, MD2 and Michael C. Milone, MD, PhD4

1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
2Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
3Department of Neurology, University of Pennsylvania, Philadelphia, PA
4Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA
5Novartis Institutes for Biomedical Research, Cambridge, MA

4:45 PM

Lingzhi Yan1*, Jingjing Shang1*, Liqing Kang2*, Xiaolan Shi1*, Jin Zhou1*, Song Jin1*, Weiqin Yao1*, Ying Yao1*, Guanghua Chen1, Ziling Zhu1*, Huirong Chang1*, Depei Wu, MD 3, Lei Yu2* and Fu Cheng Cheng, MD, PhD1*

1the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, suzhou, China
2Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China
3The First Affiliated Hosp. of Soochow University, Suzhou, Jiangsu, China

5:00 PM

Vaishali Sanchorawala, MD1, Shayna Sarosiek, MD2, John Mark Sloan, MD1, Dina Brauneis, NP1*, Mary Ellen Migre3*, Meredith Mistark3*, Stephanie Santos3*, Salli Fennessey3* and Anthony C Shelton, RN1*

1Boston Medical Center, Boston, MA
2Boston Medical Center, Boston, MA
3Boston Medical Center, Boston

5:15 PM

Murielle Roussel1*, Anne-Marie Stoppa, MD2, Aurore Perrot, MD3*, Lionel Karlin, MD4*, Bertrand Arnulf, MD, PhD5*, Margaret Macro, MD6*, Antoine Huart, MD7*, Laurent Frenzel, MD, PhD8*, Pierre Morel, MD9*, Eileen Boyle, MD10*, Veronique Dorvaux, MD11*, Giampaolo Merlini, MD 12, Giovanni Palladini, MD, PhD13, David Lavergne, PhD14*, Frank Bridoux, MD, PhD15* and Arnaud Jaccard14*

1Hematology Department, IUCT-Oncopole, Toulouse, France
2Institut J Paoli-Calmettes, Marseille, France
3Hôpitaux De Brabois, Vandoeuvre Les Nancy, France
4Ch Lyon Sud, Pierre Bénite, France
5Département d'Immuno-Hématologie, APHP, Paris, France
6Haematology Department, Caen University Hospital, Caen, France
7Department of Nephroiogy, Oncopole, Toulouse, France
8Hematology Department / Hemophilia Center, INSERM U1163, CNRS ERL 8254, Paris, France
9Department of Hematology, Chu Amiens, Salouel, FRA
10Department of Hematology, CHU, Lille, FRA
11Medecine Interne, Hopital Notre Dame de Bon Secours, Metz-Thionville, France
12Foundation IRCCS Policlinico San Matteo, University of Pavia, Italy, Pavia, ITA
13Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
14Department of Hematology and National Referral Center for AL Amyloidosis, CHU Limoges, Limoges, France
15Department of Nephrology and National Referral Center for AL Amyloidosis, CHU, Poitiers, France

5:30 PM

Camille Vanessa Edwards, MBBS, BSc1*, Julia Gould, BA2*, Arielle L Langer, MD, MPH3*, Markus Y Mapara, MD, PhD4, Jai Radhakrishnan, MD5*, Mathew S. Maurer, MD6*, Shahzad Raza, MD7, John G. Mears, MD8, Siyang Leng, MD9, Jonathan S. Wall, PhD10*, Andrew Eisenberger, MD2, Alan Solomon, MD11 and Suzanne Lentzsch, MD, PhD12

1Hematology/ Oncology, Boston Medical Center, Boston, MA
2Columbia University Medical Center, New York, NY
3Hematology/ Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
4Blood and Marrow Transplantation Program, Columbia University College of Physcians and Surgeons, New York, NY
5Division of Nephrology, Columbia University Medical Center, New York, NY
6Division of Cardiology, Columbia University, New York, NY
7Saint Luke's Cancer Institute/ University of Missouri, Kansas City, MO
8Department of Medicine, Columbia University Medical Center, New York, NY
9Division of Hematology and Oncology, Columbia University Medical Center, Sunnyside, NY
10Department of Medicine, University of Tennessee Medical Center, Knoxville, TN
11Graduate School of Medicine, University of Tennessee, Knoxville, TN
12Division of Hematology and Oncology, Columbia University Medical Center, New York, NY

5:45 PM

Craig C Hofmeister, MD1, Ajai Chari2*, Yael Cohen3*, Andrew Spencer, MD4, Peter M. Voorhees, MD5, Jane Estell6*, Christopher P. Venner7*, Irwindeep Sandhu8*, Matthew W Jenner9*, Cathy Williams10*, Michele Cavo, MD11*, Niels WCJ Van De Donk12, Meral Beksac13*, Steven Kuppens14*, Rajesh Bandekar15*, Tobias Neff16, Christoph Heuck16*, Ming Qi16*, Hartmut Goldschmidt, MD 17 and Ola Landgren, MD, PhD18

1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH
2Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
3Department of Hematology, Tel-Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel
4Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
5Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
6Haematology Department, Concord Cancer Centre, Concord Hospital, Concord, NSW, Australia
7Cross Cancer Institute, Edmonton, AB, Canada
8Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
9Southampton General Hospital, Southampton, United Kingdom
10Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom
11”Seràgnoli” Institute of Hematology Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
12Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
13Department of Hematology, Ankara University, Ankara, Turkey
14Janssen Research & Development, Beerse, Belgium
15Janssen Research & Development, LLC, Spring House, PA
16Janssen Research & Development, Spring House, PA
17University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany
18Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY

*signifies non-member of ASH